22.72
price down icon0.39%   -0.09
 
loading
Schlusskurs vom Vortag:
$22.81
Offen:
$22.81
24-Stunden-Volumen:
75,610
Relative Volume:
0.36
Marktkapitalisierung:
$324.03M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+1.70%
1M Leistung:
+34.60%
6M Leistung:
+50.86%
1J Leistung:
-46.79%
1-Tages-Spanne:
Value
$22.01
$23.17
1-Wochen-Bereich:
Value
$20.80
$23.53
52-Wochen-Spanne:
Value
$6.875
$74.49

Neurogene Inc Stock (NGNE) Company Profile

Name
Firmenname
Neurogene Inc
Name
Telefon
(877) 237-5020
Name
Adresse
535 W 24TH STREET, NEW YORK
Name
Mitarbeiter
107
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
NGNE's Discussions on Twitter

Vergleichen Sie NGNE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NGNE
Neurogene Inc
22.72 325.32M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-17 Eingeleitet Craig Hallum Buy
2025-05-16 Herabstufung Robert W. Baird Outperform → Neutral
2024-06-27 Eingeleitet BMO Capital Markets Outperform
2024-06-11 Eingeleitet Robert W. Baird Outperform
2024-04-29 Eingeleitet Leerink Partners Outperform
2024-03-21 Eingeleitet William Blair Outperform
2024-01-08 Eingeleitet H.C. Wainwright Buy
2024-01-05 Eingeleitet Stifel Buy
2024-01-04 Eingeleitet TD Cowen Outperform
Alle ansehen

Neurogene Inc Aktie (NGNE) Neueste Nachrichten

pulisher
Jul 26, 2025

Why Neurogene Inc. stock attracts strong analyst attention10x Return With Managed Risk - Metal.it

Jul 26, 2025
pulisher
Jul 26, 2025

What makes Neurogene Inc. stock price move sharplyFree Deep Market Trend Analysis - Metal.it

Jul 26, 2025
pulisher
Jul 25, 2025

Is Neurogene Inc. a good long term investmentStrong return on investment - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

What drives Neurogene Inc. stock priceAccelerated capital growth - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Neurogene Inc. Stock Analysis and ForecastExplosive capital gains - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

Rett bet set includes Neurogene, Taysha gene therapies - BioWorld MedTech

Jul 24, 2025
pulisher
Jul 22, 2025

What analysts say about Neurogene Inc. stockFree Market Dynamics Reports - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

how neurogene inc. stock performs during market volatilityDefensive Stock Picks with Upside - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

How Neurogene Inc. stock performs during market volatilityHigh Return Conservative Stocks - Newser

Jul 15, 2025
pulisher
Jul 05, 2025

Neurogene announces inducement grants - Medical Buyer

Jul 05, 2025
pulisher
Jul 03, 2025

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Jul 03, 2025
pulisher
Jul 03, 2025

Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World

Jul 03, 2025
pulisher
Jul 01, 2025

Neurogene jumps as FDA approves rare gene therapy trial design - TradingView

Jul 01, 2025
pulisher
Jul 01, 2025

Stifel reiterates Buy rating on Neurogene stock, backs pivotal trial design - Investing.com UK

Jul 01, 2025
pulisher
Jun 30, 2025

FDA approves Neurogene’s Rett syndrome gene therapy registrational trial design - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome - Business Wire

Jun 30, 2025
pulisher
Jun 30, 2025

Neurogene Inc.(NasdaqGM: NGNE) dropped from Russell 3000E Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 18, 2025

Craig-Hallum bullish on Neurogene, initiates with a Buy - Yahoo Finance

Jun 18, 2025
pulisher
Jun 18, 2025

Neurogene (NASDAQ:NGNE) Coverage Initiated by Analysts at Craig Hallum - Defense World

Jun 18, 2025
pulisher
Jun 17, 2025

Neurogene (NGNE) Receives New Buy Rating from Craig-Hallum | NGN - GuruFocus

Jun 17, 2025

Finanzdaten der Neurogene Inc-Aktie (NGNE)

Es liegen keine Finanzdaten für Neurogene Inc (NGNE) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Kapitalisierung:     |  Volumen (24h):